Dosing safety

Retatrutide Dosage Chart (2026): Why Public Charts Are Not Personal Instructions

Published May 3, 2026Updated May 3, 2026Medical safety, official-source, and research-reference review

This page does not provide a dosage chart. Retatrutide has no FDA-approved public dosing label.

Direct answer

A retatrutide dosage chart for personal use should not be copied from search results. Published trial dosing belongs to controlled research protocols, and retatrutide is not approved for public use.

Research context

These references frame the evidence base behind this topic. They are not medical advice, approval, or instructions for using retatrutide outside a clinical trial.

Short source quoteagonist of the GIP, GLP-1, and glucagon receptors

Jastreboff et al., NEJM 2023 retatrutide phase 2 obesity trial

This peer-reviewed phase 2 paper is the anchor for retatrutide mechanism language. It does not make retatrutide approved or publicly available.

Short source quoterandomised, double-blind, placebo and active-controlled

Rosenstock et al., Lancet 2023 retatrutide phase 2 type 2 diabetes trial

The type 2 diabetes phase 2 paper helps separate controlled clinical research from online self-use claims.

Short source quote10-fold dosing errors

Lambson et al., JAPhA 2023 compounded semaglutide administration-error case series

This case series supports warnings about vials, syringe units, and self-measured injectable dosing errors.

Short source quoteoverdose administration errors

Wiener et al., Clinical Toxicology 2024 semaglutide overdose administration-error case series

This toxicology case series supports caution around injection initiation and dose-measurement mistakes.

Short source quotepreparation errors

McCall et al., Expert Opinion on Drug Safety 2026 compounded GLP-1 pharmacovigilance study

This pharmacovigilance study is relevant to compounded GLP-1 safety signals and product-quality concerns.

What to know before acting on this search

There is no FDA-approved retatrutide dose, titration schedule, conversion chart, or unit chart for consumers.
Clinical-trial dose arms are designed for research questions, not general prescribing.
A dosage chart can become unsafe when a product is unapproved, concentration is uncertain, or syringe units are misunderstood.
If an approval happens later, the public dosage reference should be the FDA-approved label plus prescriber instructions.

Safety and compliance notes

Dose charts can make unverified online products look more legitimate than they are.
Dosing errors are a known concern with self-measured injectable GLP-1 products.
Do not adjust dose, frequency, or escalation based on seller tables, forum posts, or calculators.

Safer next step

Use the FDA status page and approved-alternatives page instead of trying to build a personal retatrutide chart.

Medical disclaimer

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. I am not a medical professional. Always consult a qualified healthcare provider before starting, stopping, or changing any weight loss treatment. Individual results vary. Retatrutide is investigational and is not FDA approved. FDA-approved options such as semaglutide and tirzepatide require prescriptions and should only be used under medical supervision.

References

Public record review

Have a public record we should add?

Submit a public page, correction, or observation for documentation review. Submissions are evaluated for public-record value only, not to help people obtain products.

Submit a public record